Clinical trials
Fibromyalgia trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 3 |
| 2011 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Frederiksberg University Hospital | 3 |
| Daiichi Sankyo | 2 |
| Esbjerg Hospital - University Hospital of Southern Denmark | 2 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2 |
| University College of Northern Denmark | 2 |
| Aalborg University | 1 |
| Aarhus University Hospital | 1 |
| GlaxoSmithKline | 1 |
| Marius Henriksen | 1 |
| Odense University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fibromyalgia | 20 |
| Pain | 6 |
| Chronic Pain | 5 |
| Fatigue Syndrome, Chronic | 3 |
| Irritable Bowel Syndrome | 3 |
| Arthritis, Rheumatoid | 2 |
| Fatigue | 2 |
| Muscular Diseases | 1 |
| Neurogenic Inflammation | 1 |
| Parasomnias | 1 |
Trials
Showing 26 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.